Balance Disorders News and Research

RSS
A balance disorder is a disturbance that causes an individual to feel unsteady, giddy, woozy, or have a sensation of movement, spinning, or floating. An organ in our inner ear, the labyrinth, is an important part of our vestibular (balance) system. The labyrinth interacts with other systems in the body, such as the visual (eyes) and skeletal (bones and joints) systems, to maintain the body's position. These systems, along with the brain and the nervous system, can be the source of balance problems.
EU funds ‘Keep Control’ project that focuses on balance and gait deficits in older adults

EU funds ‘Keep Control’ project that focuses on balance and gait deficits in older adults

IU researchers develop new method to grow inner ear tissue from human stem cells

IU researchers develop new method to grow inner ear tissue from human stem cells

First-ever clinical study shows that older adults benefit from hearing aid use

First-ever clinical study shows that older adults benefit from hearing aid use

Sighted people can be trained to use echolocation to estimate sizes of enclosed spaces

Sighted people can be trained to use echolocation to estimate sizes of enclosed spaces

Research highlights how the brain handles numbers

Research highlights how the brain handles numbers

Nearly 3.3 million children in U.S. have dizziness or balance problem

Nearly 3.3 million children in U.S. have dizziness or balance problem

CRISPR tool unlocks potential for novel treatments across different therapeutic areas

CRISPR tool unlocks potential for novel treatments across different therapeutic areas

Scientists use new technology to create gene expression map of inner ear cell development

Scientists use new technology to create gene expression map of inner ear cell development

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

GenVec reports net loss of $1.9 million for second quarter 2015

GenVec reports net loss of $1.9 million for second quarter 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Brittle bones does not significantly affect occurrence of bone fractures among older people

Brittle bones does not significantly affect occurrence of bone fractures among older people

GenVec reports net loss of $1.5 million for first quarter 2015

GenVec reports net loss of $1.5 million for first quarter 2015

GenVec, Laboratory of Malaria Immunology and Vaccinology sign research collaboration agreement

GenVec, Laboratory of Malaria Immunology and Vaccinology sign research collaboration agreement

GenVec reports record financial results for Q4 and fiscal year 2014

GenVec reports record financial results for Q4 and fiscal year 2014

GenVec collaborates with TheraBiologics to develop NSC-mediated cancer therapeutics

GenVec collaborates with TheraBiologics to develop NSC-mediated cancer therapeutics

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Researchers create new vestibular test to add to comprehensive concussion evaluation

Researchers create new vestibular test to add to comprehensive concussion evaluation

GenVec reports net loss of $1.7 million for second quarter 2014

GenVec reports net loss of $1.7 million for second quarter 2014

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.